达雷妥尤单抗治疗多发性骨髓瘤患者感染风险的时间趋势:一项荟萃分析
该个体患者水平荟萃分析纳入6项随机试验共2989例新诊断或复发难治多发性骨髓瘤患者,比较含达雷妥尤单抗方案与不含该药方案的2年感染事件。结果显示达雷妥尤单抗组任何级别和≥3级感染率均更高,风险在前3个月达峰后趋于平稳,调整后仍独立相关,且复发感染更常见,而预防策略使用不足。
要点
- 达雷妥尤单抗组任何级别感染79% vs 61%,≥3级感染29% vs 20%。
- 感染风险前3个月最高(42% vs 36%,p=0.001),之后趋于平稳。
- 严重呼吸道感染患者中接受免疫球蛋白替代治疗者不足20%。
核心结论
- 达雷妥尤单抗治疗多发性骨髓瘤患者感染风险增高,且存在前3个月的早期脆弱窗口。
研究设计与样本
- 个体患者水平荟萃分析,纳入6项随机试验共2989例新诊断和复发/难治多发性骨髓瘤患者,评估2年内感染事件。
主要发现
- 达雷妥尤单抗组任何级别感染率为79%,对照组为61%;≥3级感染率为29% vs 20%。
- 前3个月感染风险达峰(42% vs 36%,p=0.001),之后趋于平稳。
- 调整后达雷妥尤单抗与≥1级感染(OR 1.31,95%CI 1.10-1.57)、呼吸道感染(OR 1.38,95%CI 1.11-1.71)和≥3级感染(OR 1.47,95%CI 1.08-2.00)独立相关。
- 2年感染率调整后发病率比为1.60(95%CI 1.47-1.73),复发感染更常见(多次任何级别感染33% vs 22%;多次≥3级感染11% vs 7%)。
- 严重呼吸道感染患者中接受免疫球蛋白替代治疗者不足20%。
临床怎么用
- 应针对达雷妥尤单抗治疗患者前3个月的感染脆弱窗口加强预防和监测。
- 需关注复发感染,并提高免疫球蛋白替代等预防策略的使用率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-cluster of differentiation 38 (Anti-CD38) monoclonal antibodies such as daratumumab are widely used in multiple myeloma (MM), yet the timing and magnitude of infectious risk remain incompletely defined. We performed an individual patient-level meta-analysis of six randomized trials (N = 2989) comparing daratumumab- versus non-daratumumab-containing regimens in newly diagnosed and relapsed/refractory MM, assessing infectious events over 2 years. Daratumumab-treated patients had higher rates of any-grade (79% vs. 61%) and grade ≥3 infections (29% vs. 20%) than controls, with risk peaking in the first 3 months (42% vs. 36%, p = 0.001) before plateauing. After adjustment, daratumumab was independently associated with grade ≥1 (odds ratio [OR] 1.31, 95% confidence interval [CI] 1.10-1.57), respiratory (OR 1.38, 95% CI 1.11-1.71) and grade ≥3 (OR 1.47, 95% CI 1.08-2.00) infection by 3 months. Daratumumab-treated patients had a higher rate of infection over 2 years (adjusted incidence rate ratio 1.60, 95% CI 1.47-1.73) and more frequently experienced recurrent infections (33% vs. 22% with multiple any-grade infections; 11% vs. 7% with multiple grade ≥3 infections). Preventive strategies were underused, with <20% of patients with severe respiratory infections receiving immunoglobulin replacement. These findings identify an early window of infectious vulnerability with daratumumab and support temporally targeted prevention and monitoring strategies in contemporary MM care.
引用
- Visram A, Mian H, Lee J, et al. Temporal trends in infectious risk among multiple myeloma patients treated with daratumumab: A meta-analysis. Br J Haematol. 2026. PMID: 42928979. doi:10.1111/bjh.70882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。